Navigate FDA drug registration, DEA controlled substance permits, API sourcing compliance, and complex Chapter 28-30 classification. Multiple PGA requirements automated.
Start Free TrialPharmaceutical imports face more regulatory agencies, documentation requirements, and inspection protocols than virtually any other product category.
All drug imports must comply with FDA regulations under the Federal Food, Drug, and Cosmetic Act. This includes drug listing, establishment registration, Current Good Manufacturing Practice (cGMP) compliance, and prior notice for food-grade pharmaceutical ingredients.
Importing controlled substances (Schedules I-V) requires DEA import permits. Each shipment needs a separate permit application filed at least 15 days before import. Narcotic raw materials face additional International Narcotics Control Board quotas.
Active Pharmaceutical Ingredients (APIs) imported for drug manufacturing must come from FDA-registered establishments. Drug Master Files (DMFs) must be on file. Country of origin matters for supply chain security.
Pharmaceutical classification spans Chapters 28 (inorganic chemicals), 29 (organic chemicals), and 30 (pharmaceutical preparations). The distinction between bulk API and dosage form determines both the HTS code and the applicable duty rate.
| Product Type | HTS Chapter | Typical MFN Rate | PGA Requirements |
|---|---|---|---|
| Bulk APIs (organic) | Ch. 29 | Free - 6.5% | FDA |
| Bulk APIs (inorganic) | Ch. 28 | Free - 5.5% | FDA |
| Dosage-form drugs | Ch. 30 | Free - 6% | FDA |
| Controlled substances | Ch. 29/30 | Varies | FDA + DEA |
| Vaccines & biologics | Ch. 30 | Free | FDA (CBER) |
| Medical devices | Ch. 90 | Free - 9% | FDA (CDRH) |
Many pharmaceutical products qualify for duty-free treatment under WTO Pharmaceutical Agreement or special duty provisions. Classification determines eligibility.
Many pharmaceutical products benefit from zero-duty treatment under the WTO Pharmaceutical Agreement. However, the product must be specifically listed in the Agreement's annexes. Correct HTS classification is critical to qualifying — misclassification can result in paying duties that should be zero.
China supplies a significant share of global API production. Section 301 tariffs (25% under Lists 1-3) apply to many Chinese chemical and pharmaceutical intermediates. Importers must evaluate whether APIs from China face Section 301 tariffs on top of base MFN rates, and consider alternative sourcing from India, EU, or other regions.
Temperature-sensitive pharmaceuticals (vaccines, biologics, certain APIs) require continuous cold chain documentation throughout import. CBP and FDA may inspect cold chain records. Improper temperature excursions can result in product destruction at the port.
FDA and CBP actively screen pharmaceutical imports for counterfeit products. Imports from unregistered or uninspected foreign facilities face heightened scrutiny. Proper documentation of supply chain provenance is essential.
Classify pharmaceutical products across Chapters 28, 29, and 30. Determine WTO Pharmaceutical Agreement eligibility. Distinguish between API and dosage-form classification.
Identify which agencies (FDA, DEA, EPA) need to clear your product. See specific filing requirements, permit timelines, and inspection protocols.
Calculate duties with WTO Pharmaceutical Agreement consideration. Factor in Section 301 tariffs on Chinese APIs. Compare sourcing from India, EU, and other origins.
AI-powered classification and regulatory tools for the pharmaceutical industry.
Create Free Account